Esomeprazole, a new proton pump inhibitor: Pharmacological characteristics and clinical efficacy

International Journal of Clinical Practice

Volumn 54, Issue 8, 2000, Pages 537-541

  Thtphuree, S ^a   Talley, N J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; GASTRIN; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; PRIORITY JOURNAL;

ADULT; AGED; ANTI-ULCER AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; ESOPHAGITIS, PEPTIC; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS; TREATMENT OUTCOME;

EID: 0033739561     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Brändström A, Lindberg P. Junggren U. Structure activity relationships of substituted benzimidazoles. Scand J Gastroenterol 19X5; 20(suppl 108): 15-22.
2. Hassan-Alin M, Niazi M, Röhss K et al. Esomeprazole, the S-isomer of omeprazole, is optically stable in humans. Abstract book, XXXII Nordic Meeting of Gastroenterology, Göteborg, Sweden, June 18-21, 2000: 51.
3. Andersson T. Pharmacokinetics, metabolism, and interactions of acid pump inhibitor. Focus on omepraJ.ole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31: 9-28.
4. Andersson T, Holmberg J, Röhss K et al. Pharmacokinetic and effect on caffeine metabolism of the proton pump inhibitors, omeprazole. lansoprazole, and pantoprazole. Br J din Pharmacol 1998; 45: 369-375.
5. Andersson T, Miners JO, Tassaneeyakul W et al. High-performance liquid Chromatographie assay for human liver microsomal omeprazole metabolism. ./ Chromarogr 1993; 619: 291-297.
6. Andersson T. Bredberg E, Sunzel M et al. Pharmacokinetics and pharmacodynamics of omeprazole and its two enantiomers, S-omeprazole/ esomeprazole and R-omeprazole. Gastroenterology 2000; USisuppl 2).
7. Äbelö A. Andersson T. Bredberg U et al. Stereoselective metabolism by human liver CYP enzymes of a substituted benzimidazole. Drug Metab Dispos 2000; 29: 58-64.
8. Äbelö A. Andersson T. Antonsson M et al. Stereoselective metabolism of omepraJ.ole by human cytochrome P450 enzymes. Drug Metabol Dispos 2000; 28: 966-972.
9. Andersson T. Röhss K, Hassan-Alin M et al. Pharmacokinetics and doseresponsc relationship of esomeprazole, the S-isomer of omeprazole. Gastroenterology 2000; 118(suppl 2).
10. Hassan-Alin M. Röhss K, Andersson T et al. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Gastroenterology 2000; 118(suppl 2): A16.
11. Lind T. Rydberg L, Kylebaek A et al. Esomeprazole provides improved acid control vs omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861-867.
12. Hasselgren G, Hassen-Alin M, Andersson T et al. Pharmacokinetics of esomeprazole are not affected by age: An assessment in the elderly. Abstract book, XXXII Nordic Meeting of Gastroenterology, Göteborg. Sweden. June 18-21, 2000.
13. Sjovall H. Hagman l, Holmberg J et at. Pharmacokinetics of esomepraJ.ole in patients with liver cirrhosis. Gastroenterology 2000; 118(suppl 2): A21.
14. Andersson T, Bredberg E, Sunzel M et al. Pharmacokinetics (PK) and effect on pentagastrin stimulated peak acid output (PAO) of omeprazole (O) and its 2 optical isomcrs, S-omeprazole/esomeprazole (E) and R-omeprazole (R-O). Br J Clin Pharmacol 2000 (in press).
15. Junghard O, Hassan-Alin M, Hasselgren G. The effect of AUC and Cma.x of esomepra/olc on acid secretion and intragastric pH. Gastroenterology 2000: 118(suppl 2): A17.
16. Lind T. Cederherg C, Ekenved G et al. Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin stimulated acid secretion in man. Gut 1983:24: 270-276.
17. Röhss K. Claar-Nilsson C. Rydholm H et al. Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg. Gastroenterology 2000; 118(suppl 2): A20.
18. Wilder-Smith C. Röhss K. Lundin C et al. Esomeprazole 40 mg provides more effective acid control than pantoprazole 40 mg. Gastroentero/ogv 2000; 118(suppI2): A22.
19. Röhss K, Lundin C, Rydholm H et al. Esomeprazole 40 mg provides more effective acid control than omepraJ.ole 40 mg. Abstract book. XXXII Nordic Meeting of Gastroenterology. Göteborg, Sweden, June 18-21, 2000.
20. Kahrilas PJ. Falk G. Johnson DA et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomi/ed controlled trial. Alitnetil Phannaeol Ther 2000; 14: 1249-1 258.
21. Richter JE, Kahrilas PJ, Hwang C et al. Esomeprazole is superior to omeprazole for the healing of erosive esophagitis (erosive esophagitis) in GERD patients. Gastrvcnterology 2000; 118(suppl 2): A20.
22. Armstrong D. Bennett JR, Blum AL et al. The endoscopie assessment of esophagitis: a progress report on observer agreement. Gastroenterologe 1996; 111: 85-92.
23. Johnson DA, Benjamin SB. Whipple J et al. Efficacy and safety of esomeprazole as maintenance therapy in GERD patients with healed erosive esophagitis (erosive esophagitis). Gastroenterologe 2000: 11 Xlsuppl 2): A17.
24. Vakil NB, Shaker R, Hwang C et al. Esomepra/ole is effective as maintenance therapy in GERD patients with healed erosive esophagitis (erosive esophagitis). Gastroenterologe 2000; 11 Xlsuppl 2): A22.
25. Carlsson R, Dent J. Watts R et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole, International GORD Study Group. Eur J Gastmenterol Hepatol 1998; 10: 119-124.
26. Talley NJ, Lauristen K, Tunturi-Hihnala H el al. EsomepraJ.ole 20 mg maintains symptom control in endoscopy-negative GERD: a randomi/ed placebo-controlled trial of on-demand therapy for 6 months. Gastroenterologe 2000; 118(suppl 2): A21.
27. Talley NJ. Venables TL, Green JR et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopynegative GERD: a placebo-controlled trial of on-demand therapy for 6 months. Gastmenterology 2000; HSlsuppI 2): A658.
28. Lind T. Havelund T, Lundell L et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Thcr 1999; 13:907-914.
29. Laine L, Fennerty MB. Osato M et al. Esornepra/,ole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance. Am J Gastroeiitfrol (in press).
30. Laine L, Suchower L, Frantz J el al. Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for H. pylori eradication in duodenal ulcer disease: results of 3 multicenter. double-blind U.S. trial. Am .1 Gastmenterol 1998; 93: 2106-2112.
31. Fennerty MB, Kovacs TOG. Krause R et al. A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacler pylori. Arch Intern Med 1998; 158: 1651 -1656.
32. Fennerty MB, Laine LA, Sugg JE et al. Esomepra/ole based triple therapy is more effective than dual therapy for eradication of H. pelori. Gastroenterologe 2000: 118(suppl 2): A495.
33. Veldherg vor Zanten SJV. Laurilsen K, Delchier JC et al. 7-day triple therapy with esomeprazole, amoxycillin and clarithromycin for H. pylori (HP) eradication in duodenal ulcer (DU) disease. Gastroenterologe 2000: 118(suppl2): A503.
34. Tulassay Z, Kryszewski A, Ditr P et al. 7-day treatment with esomeprazole-based triple therapy eradicates H. pylori (HP) and heals patients with duodenal ulcer (DU) disease. Gastroenterologe 2000: 118(suppl 2): A502.
35. Malfertheiner P. Megraud F, O'Morain C et al. Current European concepts in the management of Helicobacter pylori infection - the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). Eur J Gastmenterol Hepatol 1997; 9(1): 1-2.
36. Maton P, Vakil NB, Hwang C et al. Safety and efficacy of long-term treatment with esomeprazole in patients with healed erosive esophagitis (erosive esophagitis). Gastroenterologe 2000; 11 Xlsuppl 2): A19.
37. Freston JW. Long-term acid control and proton pump inhibitors: interactive and safety issues in perspective. Am J Gastwenteml 1997; 92(suppl 1 ): 51S-55S.
38. Bateman DN. Proton-pump inhibitors: three of a kind. Lancet 1997: 349: 1637-1638.
39. Arnold R. Safety of proton pump inhibitors - an overview. Aliment Pharmacol Ther 1994; 8(suppl 1): 65-70.
40. Richter JE, Johnson DA, Magner DJ et al. Six month safety and tolerabili ty of esomeprazole as maintenance therapy in GERD patients with healed erosive esophagitis (erosive esophagitis). Gastroenterologe 2000; 118: A1299.
41. Genta RM, Magner DJ, D'Amico D el al. Safety of long-term treatment with a new PPI, esomeprazole on GERD patients. Gastroenterologe 2000: 118(suppl2): A16.
42. Klinkenberg-knol EC, Nelis F, Dent J et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosal. Gastmenterology 2000; 118: 661 669.
43. Klinkenberg-knol EC. Festen HP. Jansen .IB el al. Loivi-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994: 121: 161-167.